Literature DB >> 9557650

Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

N Zhu1, A Khoshnan, R Schneider, M Matsumoto, G Dennert, C Ware, M M Lai.   

Abstract

The hepatitis C virus (HCV) core protein is known to be a multifunctional protein, besides being a component of viral nucleocapsids. Previously, we have shown that the core protein binds to the cytoplasmic domain of lymphotoxin beta receptor, which is a member of tumor necrosis factor receptor (TNFR) family. In this study, we demonstrated that the core protein also binds to the cytoplasmic domain of TNFR 1. The interaction was demonstrated both by glutathione S-transferase fusion protein pull-down assay in vitro and membrane flotation method in vivo. Both the in vivo and in vitro binding required amino acid residues 345 to 407 of TNFR 1, which corresponds to the "death domain" of this receptor. We have further shown that stable expression of the core protein in a mouse cell line (BC10ME) or human cell lines (HepG2 and HeLa cells) sensitized them to TNF-induced apoptosis, as determined by the TNF cytotoxicity or annexin V apoptosis assay. The presence of the core protein did not alter the level of TNFR 1 mRNA in the cells or expression of TNFR 1 on the cell surface, suggesting that the sensitization of cells to TNF by the viral core protein was not due to up-regulation of TNFR 1. Furthermore, we observed that the core protein blocked the TNF-induced activation of RelA/NF-kappaB in murine BC10ME cells, thus at least partially accounting for the increased sensitivity of BC10ME cells to TNF. However, NF-kappaB activation was not blocked in core protein-expressing HeLa or HepG2 cells, implying another mechanism of TNF sensitization by core protein. These results together suggest that the core protein can promote cell death during HCV infection via TNF signaling pathways possibly as a result of its interaction with the cytoplasmic tail of TNFR 1. Therefore, TNF may play a role in HCV pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557650      PMCID: PMC109590          DOI: 10.1128/JVI.72.5.3691-3697.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system.

Authors:  D W Kim; T Uetsuki; Y Kaziro; N Yamaguchi; S Sugano
Journal:  Gene       Date:  1990-07-16       Impact factor: 3.688

2.  Serum levels of cytokines in chronic liver diseases.

Authors:  H Tilg; A Wilmer; W Vogel; M Herold; B Nölchen; G Judmaier; C Huber
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

3.  Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets.

Authors:  P Thiagarajan; J F Tait
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

4.  Monitoring the acute phase response: comparison of tumour necrosis factor (cachectin) and C-reactive protein responses in inflammatory and infectious diseases.

Authors:  C P Maury
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

5.  The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Authors:  G Mosialos; M Birkenbach; R Yalamanchili; T VanArsdale; C Ware; E Kieff
Journal:  Cell       Date:  1995-02-10       Impact factor: 41.582

6.  Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation.

Authors:  C M Shih; C M Chen; S Y Chen; Y H Lee
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

7.  Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease.

Authors:  M J Hussain; A Mustafa; H Gallati; A P Mowat; G Mieli-Vergani; D Vergani
Journal:  J Hepatol       Date:  1994-11       Impact factor: 25.083

8.  The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA.

Authors:  P J Chen; M H Lin; K F Tai; P C Liu; C J Lin; D S Chen
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

Review 9.  Characterization of HCV structural proteins expressed in various animal cells.

Authors:  Y Matsuura; T Harada; M Makimura; M Sato; H Aizaki; T Suzuki; T Miyamura
Journal:  Intervirology       Date:  1994       Impact factor: 1.763

10.  Tumorigenicity and lysis by natural killers.

Authors:  J L Collins; P Q Patek; M Cohn
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

View more
  93 in total

1.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans.

Authors:  S M Lemon; H Lerat; S A Weinman; M Honda
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

2.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

3.  Functional characterization of core genes from patients with acute hepatitis C virus infection.

Authors:  Xi Tang; Jessica Wagoner; Amina Negash; Michael Austin; John McLauchlan; Young S Hahn; Hugo R Rosen; Stephen J Polyak
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

4.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

6.  Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase.

Authors:  Soo-Ho Choi; Kyu-Jin Park; Byung-Yoon Ahn; Guhung Jung; Michael M C Lai; Soon B Hwang
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

7.  Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB.

Authors:  Y Sato; J Kato; R Takimoto; K Takada; Y Kawano; K Miyanishi; M Kobune; Y Sato; T Takayama; T Matunaga; Y Niitsu
Journal:  Gut       Date:  2006-03-31       Impact factor: 23.059

8.  Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Authors:  Pablo Sarobe; Juan José Lasarte; Aintzane Zabaleta; Laura Arribillaga; Ainhoa Arina; Ignacio Melero; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 9.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

10.  Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif.

Authors:  Björn Schwer; Shaotang Ren; Thomas Pietschmann; Jürgen Kartenbeck; Katrin Kaehlcke; Ralf Bartenschlager; T S Benedict Yen; Melanie Ott
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.